129 related articles for article (PubMed ID: 38165168)
21. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of metabolic tumor volume and total lesion glycolysis in esophageal carcinoma patients treated with definitive chemoradiotherapy.
Yildirim BA; Torun N; Guler OC; Onal C
Nucl Med Commun; 2018 Jun; 39(6):553-563. PubMed ID: 29668513
[TBL] [Abstract][Full Text] [Related]
23. FDG-PET/CT Predicts Outcome in Oropharingeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes.
Mapelli P; Broggi S; Incerti E; Alongi P; Kirienko M; Fiorino C; Dell Oca I; Fallanca F; Vanoli EG; Di Muzio NG; Gianolli L; Picchio M
Curr Radiopharm; 2017 Aug; 10(2):102-110. PubMed ID: 28412923
[TBL] [Abstract][Full Text] [Related]
24. Prediction of occult lymph node metastasis by metabolic parameters in patients with clinically N0 esophageal squamous cell carcinoma.
Moon SH; Kim HS; Hyun SH; Choi YS; Zo JI; Shim YM; Lee KH; Kim BT; Choi JY
J Nucl Med; 2014 May; 55(5):743-8. PubMed ID: 24700884
[TBL] [Abstract][Full Text] [Related]
25. Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma.
Hofheinz F; Li Y; Steffen IG; Lin Q; Lili C; Hua W; van den Hoff J; Zschaeck S
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1485-1494. PubMed ID: 30949816
[TBL] [Abstract][Full Text] [Related]
26. The value of metabolic parameters and textural analysis in predicting prognosis in locally advanced cervical cancer treated with chemoradiotherapy.
Pedraza S; Seiffert AP; Sarandeses P; Muñoz-Lopez B; Gómez EJ; Sánchez-González P; Pérez-Regadera JF
Strahlenther Onkol; 2022 Sep; 198(9):792-801. PubMed ID: 35072751
[TBL] [Abstract][Full Text] [Related]
27. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
Higgins KA; Hoang JK; Roach MC; Chino J; Yoo DS; Turkington TG; Brizel DM
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):548-53. PubMed ID: 21277108
[TBL] [Abstract][Full Text] [Related]
28. Metabolic activity determines survival depending on the level of lymph node involvement in cervical cancer.
Martinez A; Chantalat E; Angeles MA; Ferron G; Ducassou A; Daix M; Attal J; Bétrian S; Lusque A; Gabiache E
BMC Cancer; 2022 Jul; 22(1):810. PubMed ID: 35870900
[TBL] [Abstract][Full Text] [Related]
29. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer.
Miccò M; Vargas HA; Burger IA; Kollmeier MA; Goldman DA; Park KJ; Abu-Rustum NR; Hricak H; Sala E
Eur J Radiol; 2014 Jul; 83(7):1169-1176. PubMed ID: 24767630
[TBL] [Abstract][Full Text] [Related]
30. (
Scher N; Castelli J; Depeursinge A; Bourhis J; Prior JO; Herrera FG; Ozsahin M
Cancer Radiother; 2018 May; 22(3):229-235. PubMed ID: 29650390
[TBL] [Abstract][Full Text] [Related]
31. Adding maximum standard uptake value of primary lesion and lymph nodes in 18F-fluorodeoxyglucose PET helps predict distant metastasis in patients with nasopharyngeal carcinoma.
Shi Q; Yang Z; Zhang Y; Hu C
PLoS One; 2014; 9(7):e103153. PubMed ID: 25068373
[TBL] [Abstract][Full Text] [Related]
32. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
[TBL] [Abstract][Full Text] [Related]
33. Changes on Midchemoradiation Therapy Fluorodeoxyglucose Positron Emission Tomography for Cervical Cancer Are Associated with Prognosis.
Carpenter DJ; Jacobs CD; Wong TZ; Craciunescu O; Chino JP
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):356-366. PubMed ID: 31254659
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of baseline [18F]-fluorodeoxyglucose positron emission tomography parameters MTV, TLG and asphericity in an international multicenter cohort of nasopharyngeal carcinoma patients.
Zschaeck S; Li Y; Lin Q; Beck M; Amthauer H; Bauersachs L; Hajiyianni M; Rogasch J; Ehrhardt VH; Kalinauskaite G; Weingärtner J; Hartmann V; van den Hoff J; Budach V; Stromberger C; Hofheinz F
PLoS One; 2020; 15(7):e0236841. PubMed ID: 32730364
[TBL] [Abstract][Full Text] [Related]
35. FDG PET-CT in cervical cancer: relationship between primary tumor FDG uptake and metastatic potential.
Yilmaz M; Adli M; Celen Z; Zincirkeser S; Dirier A
Nucl Med Commun; 2010 Jun; 31(6):526-31. PubMed ID: 20215979
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of metabolic parameters determined by preoperative ¹⁸F-FDG PET/CT in patients with uterine carcinosarcoma.
Lee HJ; Lee JJ; Park JY; Kim JH; Kim YM; Kim YT; Nam JH
J Gynecol Oncol; 2017 Jul; 28(4):e43. PubMed ID: 28541634
[TBL] [Abstract][Full Text] [Related]
37. Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring?
Voglimacci M; Gabiache E; Lusque A; Ferron G; Ducassou A; Querleu D; Motton S; Chantalat E; Courbon F; Martinez A
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1551-1559. PubMed ID: 30729273
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of volume-based (18)F-fluorodeoxyglucose PET/CT parameters in patients with clinically node-negative oral tongue squamous cell carcinoma.
Lee SJ; Choi JY; Lee HJ; Baek CH; Son YI; Hyun SH; Moon SH; Kim BT
Korean J Radiol; 2012; 13(6):752-9. PubMed ID: 23118574
[TBL] [Abstract][Full Text] [Related]
39. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
40. 18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer.
Crivellaro C; Signorelli M; Guerra L; De Ponti E; Buda A; Dolci C; Pirovano C; Todde S; Fruscio R; Messa C
Gynecol Oncol; 2012 Oct; 127(1):131-5. PubMed ID: 22772064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
